




EVOLVING TECHNOLOGY/BASIC SCIENCERandomized study of surgical isolation of the pulmonary veins for
correction of permanent atrial fibrillation associated with mitral
valve disease
A´lvaro Albrecht, MD,a Renato A. K. Kalil, MD, PhD,a,c Luciana Schuch, MD,a
Roge´rio Abraha˜o, MD,a Joao Ricardo M. Sant’Anna, MD, PhD,a Gustavo de Lima, MD, PhD, FACC,b,c and
Ivo A. Nesralla, MD, PhDa
Objective: Chronic permanent atrial fibrillation is often due to mitral valve disease. The Cox maze procedure is
the gold standard for treating this arrhythmia. Simpler techniques and ablation methods should have their efficacy
tested in clinical practice. Our objective was to evaluate the effectiveness of surgical pulmonary vein isolation as
compared with the Cox maze procedure.
Methods: Sixty patients were randomly assigned to control group, modified maze group (Cox maze III), and sur-
gical isolation of the pulmonary veins (SPVI) group from July 1999 to October 2004. All patients had mitral valve
lesions treated concomitantly. Preoperative characteristics were similar between groups.
Results: There were 4 deaths: 3 in the Cox maze group and 1 in the SPVI group (P ¼ .31). The Cox maze group
presented longer times of extracorporeal circulation and myocardial ischemia (P<.001). The relative risk of late
postoperative development of atrial fibrillation was 0.07 in the SPVI group (P<.001; 95% confidence intervals:
0.02–0.27) and 0.195 in the Cox maze group (P¼ .002; 95% confidence intervals: 0.07–0.56) as compared with
the control group. No difference was found between the SPVI and Cox maze groups concerning prevention of
atrial fibrillation recurrence (relative risk: 0.358; P ¼ .215; 95% confidence intervals: 0.08–1.67).
Conclusions: The modified Cox maze procedure and surgical pulmonary vein isolation were similarly effective
in restoring sinus or regular rhythm in permanent atrial fibrillation associated with mitral valve disease. These
results favor the adoption of surgical isolation as a preferable technique, simpler and equally effective in control-
ling atrial fibrillation. The results also can bring further information for understanding the mechanisms involved in
origins and treatment of chronic permanent atrial fibrillation.Atrial fibrillation (AF) is the commonest sustained arrhyth-
mia,1 present in 0.4% of the general population and in
10% of the population over 60 years of age. Although the
diagnosis is simple, its treatment is complex and long term,
with unsatisfactory optimal outcomes. Its prevalence
increases evenly with aging.2,3 It is an independent risk fac-
tor associated with a 50% to 90% increase in the mortality
risk, both in male and in female subjects.4 It is often associ-
ated with advanced mitral valvular lesions. AF is the leading
cause of embolic episodes, 75% of which are cerebrovascu-
lar.5,6 The most feared complication of AF is systemic throm-
boembolism, which can lead to death or severe sequelae.
Multicenter studies show a 45% to 86% reduction in the
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doi:10.1016/j.jtcvs.2009.04.023454 The Journal of Thoracic and Cardiovascular Sufrequency of thromboembolic events with the use of war-
farin/aspirin, the annual incidence of embolic events remain-
ing between 0.4% and 3.5%, associated with the annual
incidence of deadly or severe hemorrhages of up to 2.5%
with warfarin.7-10 The antiarrhythmic drugs are not tolerated
in 10% to 15% of patients owing to side effects and often
cause potentially deadly proarrhythmic effects as well.11
The correction of a structural cardiac lesion can contribute to
the treatment of AF.12 However, recent data show that persis-
tent AF is the most important risk factor for late cerebrovascular
accident (CVA) after mitral valve replacement.13 The same
study showed that reversion to sinus rhythm through the
maze procedure virtually eliminated the risk of late CVA.
Thrombohemorrhagic events are less frequent in patients in
sinus rhythmafter correction of AF associated with mitral valve
lesions.14 In patients who receive surgical treatment for AF and
achieve reversion to sinus rhythm, the duration of therapy with
oral anticoagulants remains controversial.
In 1991 Cox15 reported results with the maze technique,
which showed the best rates of cure of AF until then, becom-
ing the gold standard for comparisons.16 This technique was
modified by others, and in some reports cryoablation was not
used.17,18 More recently, Fieguth, Wahlers, and Borst19 and
Haissaguerre and colleagues20 demonstrated that pulmonary
veins, inside the left atrium, are the main focus of triggering
and maintaining paroxysmal AF. In this situation and on thergery c August 2009
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AF ¼ atrial fibrillation
CI ¼ confidence intervals
CVA ¼ cerebrovascular accident
ECC ¼ extracorporeal circulation
ECG ¼ electrocardiogram
SPVI ¼ surgical isolation of pulmonary veins
basis of our previous experience with the maze procedure,
we devised a simpler procedure, basically cut and sew,
which actually is the part of the maze operation that isolates
the pulmonary veins, added with resection of the atrial ap-
pendix and a perpendicular incision between the circular in-
cision and the mitral valvular ring (to prevent left atrial
flutter).21,22 An initial randomized study with 30 patients
was performed, which indicated that the technique of surgi-
cal isolation of the pulmonary veins (SPVI) may show re-
sults as promising as those of the maze procedure in the
correction of AF associated with structural cardiac lesions.23
The sample of the previous study was doubled to determine
with greater statistical power which technique for treatment
of AF associated with structural cardiac disease might be
more effective.
METHODS
Sixty consecutive patients with permanent AF and fulfilling clinical and
hemodynamic criteria for elective mitral valvular correction were selected
for the study. Exclusion criteria were permanent AF of less than 6 months’
duration, age under 18 or over 79 years, left ventricular ejection fraction be-
low 20%, ongoing pregnancy at the time of surgery, reoperations, presence
of intrapericardial adhesions, reference from a cardiologist to any AF cor-
rection technique, and patient nonacceptance of the Free Informed ConsentThe Journal of Thoracic andForm. The present study was approved by the Ethical Board of the Instituto
de Cardiologia do Rio Grande do Sul/Fundac¸a˜o Universita´ria de Cardiolo-
gia on August 9, 1999.
This was a randomized controlled clinical trial. The patients were se-
lected from June 1999 to October 2004. As techniques for treatment of
AF became more popular, many patients in this period had already been
referred to surgery with indication from the cardiologist to receive specific
treatment for AF combined with mitral valve surgery. Those many cases
were excluded from randomization and this situation prolonged the duration
of the study. The population was randomized into three groups: (1) valvular
correction plus a simplified technique of surgical isolation of the pulmonary
veins (SPVI group), (2) valvular correction plus modified maze procedure
(Cox maze III) with no use of cryoablation (maze group), or (3) no proce-
dure associated with mitral valve correction (control group).
After signing a free consent form, the patients were submitted to an elec-
trocardiogram (ECG) and Doppler unidimensional and bidimensional echo-
cardiogram and referred for surgery. All patients were operated on by two
main surgeons. Immediately before the beginning of the operation, a sealed
envelope was opened to indicate the procedure to be performed. After anes-
thetic induction, patients were subjected to median sternotomy and opening
of the pericardium. Extracorporeal circulation (ECC) was instituted by arte-
rial cannulation into the ascending aorta and venous cannulation with an-
gled cannulas into the venae cavae, which were mobilized. Aortic
clamping and routine infusion of antegrade crystalloid hypothermic cardio-
plegic solution were done. Body temperature was maintained at 32C to
34C during ECC. A left longitudinal atriotomy was performed in all pa-
tients. In the control group, the valve was corrected at this point. The
maze group was subjected to the Cox maze III operation,15,16 modified,
with no use of cryoablation, which was replaced by wide dissection at the
area of the coronary sinus and cauterization of adjacent tissues. Before com-
plete atrial wall suture, the mitral valve was corrected or replaced. In the
SPVI group, the atriotomy was extended so as to enclose all four pulmonary
veins. At this point, the mitral valve was treated. A perpendicular incision
was performed from the extended atriotomy border to the annulus of the mi-
tral valve, dissecting the coronary sinus and performing electrocauterization
as described previously.17 The left atrial appendix was always excised, in
both treatment groups. After atrial suture with 3-0 monofilament polypro-
pylene in a single layer, the other valves were corrected if necessary. Amio-
darone or any other antiarrhythmic drugs were not routinely used during the
operation or in the intensive care unit.E
T
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STABLE 1. Clinical characteristics
Characteristics SPVI (n ¼ 20) Maze (n ¼ 20) Control (n ¼ 20) Total (n ¼ 60) P value
Age (y) 55.1  9.2 51.7  12.4 51.3  14.7 53  14.2 .556*
Female sex (%) 70 75 50 65 .318y
Duration of AF (mo) 31.78  31.6 35.4  38.5 24.6  32.0 30.6  35.7 .346z
Ejection fraction 62.1  11.3 64.3  7.1 63.3  7.0 63.2  8.5 .811*
Left atrium (cm) 5.32  0.8 5.99  1.6 6.21  1.16 5.84  1.16 .273*
NYHA 2.85  0.67 2.75  0.71 2.95  0.76 2.85  0.70 .679*
I (%) — — 5 1.7 .560y
II (%) 30.0 40.0 15.0 28.3
III (%) 55.0 45.0 60.0 53.3
IV (%) 15.0 15.0 20.0 16.7
Mitral lesion (%) .397y
Stenosis 55.0 45.0 25.0 41.7
Insufficiency 35.0 45.0 55.0 45.0
Mixed lesion 10.0 10.0 20.0 13.3
Etiology (%) .930y
Rheumatic 80.0 75.0 70.0 75.0
Degenerative 20 25.0 30.0 25.0
SPVI, Surgical isolation of pulmonary veins; AF, atrial fibrillation; NYHA, New York Heart Association functional class. Data appear as mean  standard deviation and frequency
(%). *Analysis of variance; yc2 test; zKruskal–Wallis test.Cardiovascular Surgery c Volume 138, Number 2 455




STABLE 2. Descriptive data according to surgical techniques
SPVI (n ¼ 20) Maze (n ¼ 20) Control (n ¼ 20) Total (n ¼ 60) P value
Mitral correction (%) .236y
Valvuloplasty 60 55 60 58.3
Bioprosthesis 30 40 15 28.3
Mechanical prosthesis 10 5 25 13.3
Associated surgery (%) 25 10 25 20 .392y
Duration of ECC (min) 99.85  23.8a 122.95  21.0b 62.0  23.8c 94.93  33.9 <.001*
Duration of ischemia (min) 74.7 5  19.2a 78.50  15.9a 45.10  21.1b 66.12  23.9 <.001*
Rhythm at discharge (%) <.001y
Sinus/atrial 80 75 15 56.7
PAF/flutter 20 25 85 43.3
SPVI, Surgical isolation of pulmonary veins; ECC, extracorporeal circulation; PAF, permanent atrial fibrillation. Data appear as mean  standard deviation and frequency (%).
*Analysis of variance; yc2 test. Noncoincidental index letters (a, b, c) represent statistically significant differences through the Duncan procedure of multiple comparisons.Blood and blood products were routinely used to maintain hematocrit
value over 30%, and there were no differences between groups regarding
transfusions.
Before hospital discharge, all patients who were not in regular rhythm
were subjected to electrical cardioversion and their rhythm maintained
with oral amiodarone if it reverted to sinus rhythm. Two months after the
operation, the patients returned to a specific clinic to be subjected to an
ECG and a clinical evaluation. Afterward, the patients were to return to
the clinic for a new ECG, echocardiogram, and treadmill stress test every
6 months for 24 months, after which they were followed up on a 6-month
basis with ECGs. The patients who failed to return were contacted by tele-
phone. However, the rhythm was always evaluated by ECG. The medica-
tions prescribed by the assistant cardiologists were not modified.
All obtained data were fed into Microsoft Excel XP (Microsoft Corpora-
tion, Redmond, Wash) and processed with SPSS system for statistics (SPSS
13.0 for Windows, SPSS Inc, Chicago, Ill) software. Continuous variables
were expressed as mean  standard deviation. Comparisons were made
with the c2 test for categorical variables. Cornfield analysis and Fisher’s ex-
act tests were also used as indicated. The Kruskal–Wallis test, analysis of
variance, and the Duncan procedure of multiple comparisons for continuous
variables were also used. Kaplan–Meier curves were compared by the log–
rank test.
A critical alpha of .05 was used for these comparisons to be considered as
statistically significant.
RESULTS
Table 1 shows that the groups were statistically similar in
all variables analyzed before the operation. The mean age of
patients undergoing surgery was 53  14.2 years, and
66.7% were female. Mean New York Heart Association456 The Journal of Thoracic and Cardiovascular Surfunctional classification was 2.85 0.70. Mitral stenosis oc-
curred in 41.7%, mitral insufficiency in 45%, and mixed
mitral lesion in 13.3% of the patients. The prevalence of
rheumatic disease was 75%, and 18.3% of the patients
had previous cerebral thromboembolism (Table 1).
By analyzing the mitral correction technique, we ob-
served that valvuloplasty was the most common technique
used (58.3% of the patients), followed by mitral biopros-
thesis (28.3%) and mechanical mitral prosthesis (13.3%)
(Table 2). Aortic valvuloplasty was performed in 3.3% of
the patients, tricuspid valvuloplasty in 11.7%, and atriosep-
toplasty in 1.7% (P ¼ .312 for differences between the
groups). The mean time of ECC was about 23 minutes lon-
ger in the maze group than in the SPVI group (P<.001) be-
cause of the time required for performing the incisions and
sutures in the right atrium, done on the beating heart. How-
ever, the time of myocardial ischemia did not differ between
these groups; it differed only as compared with the control
group (Table 2).
P wave morphology may be deformed after the maze pro-
cedure. Given the ECG difficulty of characterizing the sinus
rhythm in this group, we considered both sinus and atrial
rhythm as success. At hospital discharge, the SPVI group
had the highest success rate, with an 80% rate of reversion
to sinus rhythm (P<.001). The maze group achieved a suc-
cess rate of 75%, and in the control group only 15% of theTABLE 3. Patient follow-up
Characteristics SPVI (n ¼ 20) Maze (n ¼ 20) Control (n ¼ 20) Total (n ¼ 60) P value
Time (mo) 39.18  19.3 31.35  23.4 36.1  16.9 35.54  20 .468*
Rhythm (%) <.001y
Sinus 90% 85% 30% 68.3%
PAF 10% 15% 70% 31.7%
NYHA 1.20  0.52 1.35  0.74 1.45  0.68 1.33  0.65 .486*
I (%) 85 80 65 76.7 .346y
II (%) 10 5 25 13.3
III (%) 5 15 10 10
Mortality (%) 5 15 — 3.9 .153y
SPVI, Surgical isolation of pulmonary veins; PAF, permanent atrial fibrillation; NYHA, New York Heart Association functional class. Data appear as mean  standard deviation
and frequency (%). *Analysis of variance; ANOVA; yc2 test.gery c August 2009




Spatients were discharged in sinus rhythm (P< .001). After
a mean follow-up of 35  20 months, with no difference be-
tween the groups, the SPVI group had the highest rate of
conversion to sinus rhythm (90% of the patients), followed
by the maze group (85%). The control group had a 30% rate
of sinus rhythm (P<.001) (Table 3; Figure 1, A). At the end
of the follow-up, the New York Heart Association functional
class turned to 1.33  0.65, with no difference between the
groups, ascribable to correction of structural cardiopathy
rather than presence of regular rhythm (Table 3; Figure 1, B).
The results show a great difference concerning the recur-
rence of AF as the control group is compared with the treat-
ment groups (Table 4). The relative risk of AF development
was 0.07 in the SPVI group (P< .001; 95% confidence in-
FIGURE 1. A, Kaplan–Meier curve showing the number of patients at si-
nus rhythm as a function of time, according to surgical technique. B, Patient
follow-up according to presence of regular rhythm at 12-month intervals.The Journal of Thoracic andtervals [CI]: 0.02–0.27) and 0.195 in the Cox maze group
(P¼ .002; 95%CI: 0.07–0.56) as compared with the control
group, thus evidencing a strong protective effect against AF
recurrence. However, as the SPVI group was compared with
the maze group in the prevention of AF recurrence, there
was no difference between the groups (relative risk 0.358;
P ¼ .215; 95% CI: 0.08–1.67).
Morbidity and mortality are listed in Tables 5 and 6.
With regard to medication, the control group had the
greatest percentage of patients receiving anticoagulants
(Figure 2). Among all patients selected, amiodarone use at
1, 12, 24, and 36 months was 33.3%, 40%, 38.6%, and
41.9%, respectively, and digoxin use at the same intervals
was 50.9%, 49.1%, 47.7%, and 54.8%.
The analysis of thromboembolic or hemorrhagic events
did not reveal any difference in the follow-up (P ¼ .059)
(Figure 3), although patients in the control group did tend
to have more events. By thromboembolic or hemorrhagic
event, we mean any sign that is clinically perceived by the
patient or that causes him or her damage, whether it is epi-
staxis, hematuria, digestive bleeding, petechiae, thrombosis
of mechanical prosthesis, or ischemic or hemorrhagic CVA.
As a whole, the incidence of atrial flutter was low. This
arrhythmia was more prevalent within the first 6 months, oc-
curring only sporadically later in follow-up. One patient in
the SPVI group had two episodes of atrial flutter at 2 and
at 60 months. Two patients in the maze group and 2 patients
in the control group, all of them at variable periods of time,
had 12 episodes of the arrhythmia, all successfully treated
with amiodarone.
COMMENTS
The maze procedure15 is considered to be the gold stan-
dard for comparisons24,25 of new emerging techniques for
treating AF. However, wide acceptance of it has been diffi-
cult owing to its technical complexity. A number of modifi-
cations to the maze procedure have demonstrated a success
rate of around 85% in the maintenance of sinus rhythm after
valvular surgery combined with a procedure for AF.26-28
These new techniques often use energy sources such as radio-
frequency,29 ablation with microwaves,30 or cryoablation.31
Energy source equipment for performing those techniques is
often unavailable in many centers that are not referrals for
arrhythmia surgery and add costs.TABLE 4. Recurrence of AF according to technique
Group
PAF recurrence
(first event) Patients/ mo
PAF incidence
(per 100 pt-mo) RR 95% CI* P valuey
Control (n ¼ 20) 14 366.00 3.83 1 — —
Maze (n ¼ 20) 4 536.06 0.74 .195 0.07–0.56 .002
SPVI (n ¼ 20) 2 749.50 0.26 .070 0.02–0.27 <.001
SPVI vs maze — — — .358 0.08–1.67 .215
AF, Atrial fibrillation; PAF, permanent atrial fibrillation; Patients/mo, the expected length of time in follow-up for one to develop the first atrial fibrillation episode; RR, relative risk;
CI, confidence interval; SPVI, surgical pulmonary vein isolation. *Cornfield analysis; yFisher’s exact test.Cardiovascular Surgery c Volume 138, Number 2 457




SSince the pulmonary vein ostia were not manipulated in
this series, we did not expect any cases of pulmonary vein
stenosis, as confirmed by our follow-up.
Ectopic foci originating from the pulmonary veins can act
as triggers and reinitiate chronic AF,19,27 and their ablation
can prevent the reappearance of arrhythmia. The isolation
of these foci, performed in the SPVI group, was perhaps
the factor responsible for the favorable outcomes here de-
scribed. There is a research line that claims that continuous
AF does not depend on pulmonary veins for its induction or
perpetuation32 and that the mere isolation of pulmonary
veins would only confine the trigger of intermittent AF.
However, this was not observed in this series, where the re-
sults obtained regarding reversion to sinus rhythm were sta-
tistically similar between the group that received complete
maze surgery and the one treated by SPVI. Inasmuch as
the SPVI procedure does not involve incisions into the right
atrium, cases of right atrial flutter postoperatively could be
expected, and this occurred in few patients, reverting to si-
nus rhythm with amiodarone. Left atrial flutter prevention
was achieved by adding the perpendicular mitral incision,
as described in the Methods section. The study population
consisted mainly of patients with rheumatic mitral disease,
and this must be considered when discussing these results.
The control group was receiving more anticoagulant med-
ication than the intervention groups during the follow-up,
TABLE 5. Morbidity according to surgical technique






Bilateral pleural effusion 1
Mediastinitis 1
Immediate reoperation for bleeding 1
Late reoperation for mechanical
prosthesis
1 2




Low GI bleeding 1
Total 3 5 8
SPVI, Surgical pulmonary vein isolation; CVA, cerebrovascular accident; MI, myocar-
dial infarction; GI, gastrointestinal. n ¼ 20 in each group.
TABLE 6. Mortality period and causes
Group Gender Age (y) Postop. Cause
SPVI Female 71 Day 15 ARFþseptic shock
Maze Female 77 Immediate Tamponadeþ reoperation
Maze Male 73 Day 57 ARFþseptic shock
Maze Female 65 20 mo Coronary artery dissection
during catheterization
SPVI, Surgical pulmonary vein isolation; ARF, acute renal failure.458 The Journal of Thoracic and Cardiovascular Suand this did not mean reduction in the number of thrombo-
embolic events, while maintaining the bias of being able
to promote adverse hemorrhagic events. We cannot affirm
that our hemorrhagic complications in this series are higher
than our standards.
Our valvuloplasty techniques do not include mitral rings
of any kind, because although they are widely available
we favor nonsupported mitral annuloplasty both in rheu-
matic and in degenerative mitral valve insufficiency. We
observed more cases of mitral insufficiency in the control
group, and that could have led to more late reoperations.
From the clinical point of view, the patients in the three
groups had significant improvement in functional class. How-
ever, this improvement was due to the correction of the valve
lesion and occurred in similar fashion across the three inter-
vention groups. As regards deaths, the complications pre-
sented might indirectly be ascribed to the surgery for AF,
inasmuch as the longer time of ECC theoretically could be
associated with greater complications postoperatively.
Many patients were admitted to the hospital with a recom-
mended indication for treatment for AF, by maze or SPVI,
FIGURE 2. Percentage of anticoagulated patients as a function of treat-
ment group at 12-month intervals.
FIGURE 3. Kaplan–Meier curve showing the number of patients free from
thrombohemorrhagic events as a function of time according to surgical
technique.rgery c August 2009




Sthereby being excluded from randomization. This might
constitute a bias in selection. All patients without a specific
recommendation were randomized so long as they fulfilled
the inclusion criteria. As in the outpatient follow-up, the
physician was aware of the group to which the patient be-
longed, and this may have constituted a treatment bias. All
patients with AF were intensely treated so as to revert the ar-
rhythmia to sinus rhythm, and this contributed to a greater
reversion rate in the control group compared with that ex-
pected in the literature.12 Indeed, the patients in this study
as a whole were subjected to a treatment package to revert
AF, which encompassed surgery itself, peroperative care,
and strict follow-up in a dedicated outpatient clinic.
CONCLUSIONS
In conclusion, SPVI presented similar early and late resto-
ration of sinus or atrial rhythm, as compared with the mod-
ified Cox maze procedure, without cryoablation, for AF
associated with mitral valve disease in a predominantly
rheumatic population. Both techniques were highly effective
for rhythm restoration when compared with correction of the
valve lesion alone. These results favor the adoption of SPVI
as a preferable technique, simpler and equally effective in
controlling AF. The results also can bring further informa-
tion for understanding the mechanisms involved in chronic
permanent AF origins and its treatment.
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